Limited Competition for the Data Coordinating Center of Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01)

The summary for the Limited Competition for the Data Coordinating Center of Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Limited Competition for the Data Coordinating Center of Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01): This Funding Opportunity Announcement (FOA) invites an application from the Program Director/Principal Investigator current awardee of the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Data Coordinating Center (DCC) (AMP T2D-GENES DCC). The AMP T2D-GENES consortium will consist of the DCC as well as participating sites being solicited by the companion FOA. The mission of AMP T2D-GENES is to characterize the genetic variations in human genomic regions that have been putatively associated with type 2 diabetes (T2D) and conduct follow-up functional studies of particular genetic variants. This is a one-time FOA to provide funds to the AMP T2D-GENES DCC to continue the development of the web portal and deposit, aggregate and process the data generated, as part of an ongoing consortium of AMP T2D-GENES investigators as well as T2D-GENES community, for a maximum of five years, contingent on satisfactory performance. To support the conduct of these studies, AMP T2D-GENES DCC will coordinate manage and support the centers and provide the administrative infrastructure for the NIDDK-funded AMP T2D-GENES consortium. The AMP T2D-GENES DCC will build on and expand the previous work of the T2D GENES consortium.

Federal Grant Title:	Limited Competition for the Data Coordinating Center of Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Food and Nutrition Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DK-14-503
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.847
CFDA Descriptions:	Diabetes, Digestive, and Kidney Diseases Extramural Research
Current Application Deadline:	Jul 18, 2014
Original Application Deadline:	Jul 18, 2014
Posted Date:	Apr 25, 2014
Creation Date:	Apr 25, 2014
Archive Date:	Aug 18, 2014
Total Program Funding:	$2,500,000
Maximum Federal Grant Award:	$2,500,000
Minimum Federal Grant Award:	none
Expected Number of Awards:	1
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following:
Only the current awardee serving as the Data Coordinating Center of Multiethnic Study of Type 2 Diabetes Genes consortium (T2D-GENES) is eligible to apply for this Funding Opportunity Announcement.

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-503.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial...; • Adaptation of Diabetes Control Technologies for Older Adults with T1D (R01 Clinical Trial...; • Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortiu...; • Diabetes Research Centers (P30 Clinical Trial Optional); • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes; • Molecular Therapy Core Centers; • Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...